Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Mallinckrodt
Boehringer Ingelheim
McKinsey
Merck

Last Updated: June 26, 2022

Details for Patent: 8,299,298


✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,299,298 protect, and when does it expire?

Patent 8,299,298 protects AURYXIA and is included in one NDA.

This patent has eighty-six patent family members in twenty countries.

Summary for Patent: 8,299,298
Title:Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.
Inventor(s): Chan; Keith (Rockville, MD), Town; Winston (Hong Kong, CN)
Assignee: Globoasia, LLC (Rockville, MD)
Application Number:13/289,048
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,299,298
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,299,298

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Keryx Biopharms AURYXIA ferric citrate TABLET;ORAL 205874-001 Sep 5, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,299,298

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004213819 See Plans and Pricing
Australia 2006279333 See Plans and Pricing
Australia 2007210090 See Plans and Pricing
Australia 2007210096 See Plans and Pricing
Canada 2516471 See Plans and Pricing
Canada 2619591 See Plans and Pricing
Canada 2640763 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Johnson and Johnson
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.